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Lewis, M.S.N.3, Julie E. Becker, M.S.N.3, and Kim Kopenhaver Doheny, Ph.D.1
1Penn State Hershey Children’s Hospital and Department of Pediatrics, Pennsylvania State 
University, College of Medicine
2Department Of Obstetrics And Gynecology At North Shore University Hospital, Manhasset, New 
York
3Department of Nursing, Penn State Hershey Children’s Hospital and The M.S. Hershey Medical 
Center, Hershey PA.
Abstract
Aim—Skin conductance (SC) provides an objective measure of autonomic system regulation 
through sympathetic-mediated filling of sweat glands. This study aimed to test the utility of SC to 
detect sympathetic activation in neonatal abstinence syndrome (NAS).
Methods—14 term (mean, SE: 38.8 ± 0.35 weeks gestational age) neonates with chronic prenatal 
opiate exposure were enrolled. SC (peaks/sec and mean of peaks) were measured at baseline, 
during heel lance/squeeze (HLS) and recovery from HLS at 24-48 (mean 38) hours of life prior to 
treatment for NAS. Blinded coders with established reliability assessed neonates using the 
Modified Finnegan Neonatal Scoring System (MFNSS). Non-parametric tests were used to 
determine group differences, phase differences from baseline to HLS and HLS to recovery, and 
associations between MFNSS and SC measures.
Results—Neonates that would later require morphine treatment for NAS (n = 6) had higher 
baseline SC mean of peaks than those that did not require treatment (n = 8) (P<0.05). Moreover, 
there were unique phase differences between groups and SC positively correlated with MFNSS 
(P< 0.05).
Conclusion—SC provides early identification of NAS severity. However, a larger sample is 
needed to determine sensitivity and specificity of SC for early identification of NAS and treatment 
effectiveness.
Corresponding author: Kim Kopenhaver Doheny, Ph.D., Associate Professor of Pediatrics, & Director of Clinical Research, Penn 
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INTRODUCTION
Opioid use in pregnancy is an important public health issue. Both prescribed and illicit 
opiate use in pregnancy is on the increase (1). The 2010 National Survey on Drug Use and 
Health reported that an estimated 4.4% of pregnant women admitted to illicit drug use in the 
past 30 days(2). Neonates born to chronic opioid users are at risk for developing Neonatal 
Abstinence Syndrome (NAS), a constellation of acute manifestations of opioid withdrawal 
which presents early in the postnatal period. The epidemic is sizeable such that by 2009, one 
infant per hour was born with NAS in the United States (3, 4). The use of prescription opiate 
use amongst pregnant women is a growing concern, with increased incidence of NAS 
symptoms and low birth weight in exposed infants (5). Opioids act by inhibiting the release 
of norepinephrine at synaptic terminals. A sudden discontinuation of exogenous opiates 
results in higher levels of norepinephrine, characterized by central nervous system 
irritability and gastrointestinal dysfunction (6). NAS clinical manifestations commonly 
include irritability, tremors, seizures, sweating, high-pitched cry, temperature instability, 
tachypnea, uncoordinated suck/swallow reflexes, feeding difficulties, vomiting and diarrhea 
(6). The onset and severity of these symptoms can vary depending on the type of opioid the 
infant was exposed to in utero. According to the Center for Substance Abuse and Treatment, 
infants exposed to methadone may exhibit withdrawal symptoms anytime in the first 2 
weeks of life, but usually do so within 72 hours of birth, with symptoms lasting days to 
weeks, whereas infants exposed to buprenorphine develop symptoms within 12–48 hours of 
birth that peak at 72–96 hours and resolve by 7 days (7). The consequences of acute opioid 
withdrawal in neonates may be severe, resulting in significant morbidity and even mortality 
for some. Furthermore, those infants afflicted with NAS remain at risk for long-term adverse 
neurobehavioral outcomes (8, 9).
Early diagnosis and treatment of NAS is critical for promoting the best outcomes for these 
infants. The Finnegan Scoring System remains the most commonly used tool for the 
diagnosis of NAS, though it is known to be quite subjective (10, 11). Therefore the need for 
an objective measure in the assessment NAS is underscored.
Skin conductance (SC) provides real time, continuous measurement of sympathetic nervous 
system (SNS) activity that has potential for use in NAS diagnosis and monitoring. SC 
reflects bursts of SNS activity through detection of palmar and plantar sweating. Sweat 
release is controlled by the cholinergic sympathetic nervous system, as well as increased 
catecholamine response following a stressful condition (12).This is particularly increased in 
the palms and soles, where the stratum corneum, epidermis, and eccrine sweat glands are 
dense. With sympathetic activation, there are quantifiable increases in the number and 
amplitude of electrodermal or skin conductance responses. The use of SC has been well 
documented in term and preterm infants with conditions associated with pain, stress, and 
arousal (12-15). SC also has been demonstrated to be a better measure of SNS activation 
than heart rate or blood pressure, because it is not affected by hemodynamic variability (16). 
However, what is unknown is the extent to which SC provides information on SNS 
activation associated with neonatal opiate withdrawal. The primary aim of this study was to 
test the utility of skin conductance (SC) to detect sympathetic activation in neonatal 
abstinence syndrome (NAS). We hypothesized that those infants with high skin conductance 
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levels at baseline and with a painful stimulus such as a heel lance would also have high 
scores on the Modified Finnegan Neonatal Scoring System (MFNSS) and require 
pharmacological intervention.
METHODS
Ethics
The study protocol was reviewed for ethical and regulatory compliance and approved by the 
institutional review board at the study site. Informed, written parental consent was obtained 
for each study subject.
Participants and setting
This study was an observational, feasibility study with each NAS infant serving as her/his 
own control. The setting was a level IV tertiary referral neonatal intensive care unit (NICU) 
and a newborn nursery, located within an academic medical center in south central 
Pennsylvania, USA. Fourteen term NAS infants, post-menstrual age of 37weeks to 41 
weeks, with hemodynamic and cardio-pulmonary stability after birth, were enrolled during 
November 2012 to January 2014. Mothers of study subjects were identified by the 
perinatologist providing care to be opiate dependent, with chronic use during pregnancy 
(defined as greater than one intrapartum month), but without other significant co-morbidities 
(i.e. diabetes, pre-eclampsia). Exclusion criteria were: infants requiring mechanical 
ventilation, major congenital anomalies, hypoglycemia, perinatal exposure to magnesium 
sulphate, and maternal poly drug use.
Procedure
A review of the electronic medical record (EMR) was performed for detailed maternal 
medical history and neonatal demographics including: Apgar scores, exposure to magnesium 
sulphate, anesthetic agents, and NAS symptomatology and treatment course. Following 
birth, all study infants were admitted to the newborn nursery to room-in with their mothers, 
per standard clinical practice. Prenatal exposure to opiates was confirmed by positive 
toxicology of infants’ meconium.
The standard duration for observation and monitoring of NAS, using the Modified Finnegan 
Neonatal Scoring System (MFNSS) was five days. Infants with scores consistently low on 
MFNSS (below 8) were discharged after five days of observation, while the infants with 
three consecutive scores above 8, or two scores averaging more than 8, were admitted to the 
NICU for further assessment and treatment.
The evaluation of infant response to noxious stimuli was done by observing the response to 
blood sampling (heel lance/squeeze) performed as part of the state mandatory newborn 
metabolic screen done at 24-48 hours of age. This was an observation of routine care, thus 
infants were not subjected to any painful stimulus as part of the research. Study infants were 
given standard routine comfort care prior to and during the blood sampling , which included 
use of non-nutritive sucking, facilitating self-consoling supportive measures (hands to face, 
bracing of extremities), and providing tucked and flexed positioning with a snug wrap. Heel 
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lance was performed using a standard lancet, by an experienced nurse after 10 minutes of 
baseline skin conductance (SC) recording. SC measurement continued during the heel lance 
and squeezing for blood collection, and for additional 10 minutes following completion of 
blood collection. The heel lance was performed preferentially on the opposite foot, to avoid 
artifact movement to the SC electrodes. During the baseline phase there was no direct 
stimulation (i.e. handling or care). The stimulus phase, on the other hand, consisted of heel 
warming, skin prep, and the pain phase beginning with heel-lance through termination of 
heel squeeze during which the infants’ responses were measured. The recovery phase was 
the 10-minute period following heel-lance/squeeze. SC measures were obtained 
continuously during the 30 minute observation period, and later analyzed off-line in 
baseline, stimulus, and recovery epochs. Figure 1 depicts a sample registration of SC.
Skin conductance apparatus and software
Skin conductance (SC) activity was measured using the Med-Storm TM device (MedStorm, 
Oslo, Norway). The electrical conductance measured by low frequency indicates the ionic 
conduction across the stratum corneum of the skin, determined by sweat duct filling (17). To 
measure SC activity, three surface electrodes (Conmed ® Corporation, Utica NY, USA) 
were applied to the infants’ foot as directed by the manufacturer (18). The electrode system 
consists of a measuring electrode, a counter current electrode, and a reference voltage 
electrode, to ensure a continuous applied voltage across the stratum corneum beneath the 
measuring electrode, as previously described (18-21).
The observation/measurement session was standardized to time of day (afternoons, between 
12-4pm) and was done after nursing care and post-feeding, in a quiet area with low light and 
ambient temperature, to control for extraneous factors known to impact autonomic system 
measurement (i.e. circadian fluctuations, feeding and handling cycles) (13, 22). In addition, 
we ensured that no painful procedure, such as circumcision or phlebotomy, occurred on the 
day that we obtained SC measures. Skin conductance data were analyzed offline, using a 
software package provided by the manufacturer (Med Storm Innovation, Oslo Norway). SC 
measures included the number of electrodermal responses (EDRs) over time, expressed as 
peaks/sec, the average amplitude of the response, expressed as mean of peaks (μsiemens), 
and the background, or unstimulated basal level (μsiemens). While the basal activity could 
be dominated not by sympathetic activation per se but by a general restlessness, peaks per 
second and mean amplitude of peaks represent the strength and sustainability of each sweat 
gland burst and thus are most representative of sympathetic arousal. In addition, Storm has 
shown that by processing this signal with filtering both ‘noise’ and potential artifacts can be 
minimized (14).
Inter-observer reliability for Modified Neonatal Finnegan Scoring System
Nursing education related to the assessment and scoring of newborns experiencing NAS is 
included in the orientation for new nurses. Depending on prior experience, nurses hired for 
the well-baby nursery (WBN) and the neonatal intensive care unit (NICU) receive additional 
didactic training as self-study or classroom format. The training content is based upon the 
Gateway Health Plan DVD, Neonatal Abstinence Syndrome: Assessing the Infant, available 
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from: https://www.gatewayhealthplan.com/sites/default/files/documents/
PAMA_neonatal.pdf
For this study, eight nurses with expertise in the care of NAS infants were identified. These 
nurses completed an additional independent study of Assessing Signs & Symptoms of 
Neonatal Abstinence Using the Finnegan Scoring Tool: An Inter-Observer Reliability 
Program© http://www.neoadvances.com/ . The program included a review of scoring 
criteria and an assessment of an infant case scenario, followed by a comparison of the 
participant’s MFNSS score with that of the expert author. Successful completion of the 
program required a minimum 90% agreement with the author. Approximately 6 months after 
the initial inter-observer reliability assessment, a second assessment was completed to 
ensure ongoing inter-rater agreement >85% as has been previously described (23).
Statistical analysis
SPSS (IBM version 21, Chicago, Illinois) was used for data entry and analyses. Mann-
Whitney U (non-parametric test) was used to compare continuous variables between treated 
and non-treated groups, while Spearman’s correlation coefficients were used to test the 
relationships between the Finnegan scores and the SC measures. For within group 
comparisons, Wilcoxon Signed Rank tests were used to test phase differences in SC 
response at baseline (pre heel lance/squeeze) with pain phase (heel lance/squeeze), and pain 
phase with recovery phase (post-heel lance/squeeze). A value of P<0.05 was used for all 
tests of significance.
RESULTS
Demographic information
Fourteen term infants that met the eligibility criteria for the study were enrolled. The mean ± 
SE gestation for infants was 38.8 ±0.35weeks; birth weight was 2850.8±120 grams; and 
11(78.6%) were delivered vaginally. None of the study infants was depressed at birth; their 
median 5-minute Apgar score was 9 (7-9). None of those enrolled required pharmacologic 
treatment for NAS (MFNSS scores were below 8) at the time of the baseline SC 
measurements. Six (43%) of the infants studied required subsequent treatment for NAS with 
morphine by 72 hours of life. Seventy percent of subjects’ mothers were identified by the 
maternal and fetal medicine (MFM) team and maintained on the methadone program. Other 
opiate use (i.e. morphine, buprenorphine and oxycodone) in mothers accounted for 30% of 
substance use. All study mothers reported to continue cigarette smoking during this 
pregnancy. Infant and maternal characteristics are presented in Table 1.
Descriptive results
The measurement session lasted mean ±SE duration of 30.1 ± 1.1 minutes and occurred 
between 24-48 hours of life (mean 38hrs of life). MFNSS done by nurse coders within 1-2 
hours of the SC measurement was median (IQR) of 5 (4-10) for the full sample and 10 
(8-12) and 4 (3-5) for treatment and non-treatment groups respectively. Skin conductance 
obtained at baseline (pre-heel lance/squeeze) for the full sample was basal of 12.7 ±11.5 
μsiemens, peaks/sec of 0.22 ± 0.3, and mean of peaks of 0.07 ±0.1 μsiemens. There was a 
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marked difference between groups at baseline such that those infants with 3-fold higher 
values of skin conductance measures across all three parameters (basal, peaks/sec, and mean 
of peaks) later required pharmacologic treatment for NAS.
Between and within group differences
Both gestational age (GA) and postnatal age in hours at the time of measurement were 
similar between groups. Infants in the group requiring later treatment with morphine by 72 
hours of life had higher birthweights; however, none of the study infants were large for 
gestational age at birth (Table 2). The results of a two-group comparison indicated that 
infants with higher basal skin conductance levels at baseline (pre-heel lance/squeeze) and 
higher SC mean of peaks at both baseline and recovery (post-heel lance/squeeze), later 
required treatment with morphine by 72 hours of life (Table 2). There were no SC 
differences between groups during the pain phase (heel lance/squeeze). However, for the 
within group comparisons there were significantly higher phase differences in peaks/sec 
from baseline to pain phase, and pain phase to recovery in the non-treatment group; with P 
values of 0.01 and 0.03 by Wilcoxon Signed Rank tests, respectively. Conversely, those 
infants that would later require treatment for NAS by 72 hours of life had a significant phase 
difference in peaks/sec from pain phase to recovery of P = 0.04.
Correlations
In the full sample of infants (N=14), the baseline (pre-heel lance/squeeze) SC mean of peaks 
showed a direct positive correlation with MFNSS, with Spearman’s correlation coefficient 
of 0.65, P=0.01(Figure 2). Basal SC also was directly correlated with MFNSS, with 
Spearman’s correlation coefficient of 0.58, P=0.03. In contrast, peaks/sec did not correlate 
with MFNSS.
DISCUSSION
To our knowledge, there are no published studies in NAS infants that have examined 
infants’ sympathetic arousal to noxious stimuli using skin conductance. The results of the 
present study revealed that infants that had higher SC mean of peaks during both baseline 
(pre-pain) and recovery (post-pain) phases at less than 48hrs went on to require 
pharmacologic treatment with morphine by 72 hours of age. The height of mean peak 
amplitude of SC, strength of the sweat gland burst, represents higher sympathetic activation 
in these infants.
A second key finding in this investigation, is that there were clear differences in pain 
responses (during heel lance/squeeze) when comparing the group of infants that would not 
require pharmacologic treatment for opiate withdrawal as opposed to those infants that 
needed morphine treatment for NAS by 72 hours. Those infants that would not require later 
pharmacotherapy for NAS had significant increases in SC responses (peaks/sec and mean of 
peaks) during both the pre-pain to pain phase, and the pain to recovery phase, showing an 
expected sympathetic response to the pain stimulus of heel lance/squeeze for blood 
sampling. In contrast, those infants that would later require pharmacotherapy for NAS by 72 
hours had markedly higher baseline (pre-pain) peaks/sec than those that did not require 
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subsequent treatment, and in this group there was only a single between phase differences in 
peaks/sec from the pain to recovery phase. We speculate that fewer phase differences in the 
treatment group were secondary to an already high sympathetic arousal phenomenon at 
baseline (pre-pain stimulus), or a “ceiling effect”, such that, even with a painful stimulus no 
further arousal occurred.
Our findings are consistent with other studies which have shown mean of peaks and 
peaks/sec increase significantly with stimuli such as heel lance, noise, and other stimuli (12, 
13, 18, 24). Dalal et al (2013) reported a similar finding when SC was applied in post-
operative pediatric (6-12 months of age) patients recovering from anesthesia. In this study, 
the mean of peaks and basal levels were more sensitive measures of autonomic arousal than 
peaks/sec in the post-operative period in pediatric patients (25). They analyzed acute 
behavioral pain scores and SC measures, finding that peak amplitude of SC served as the 
best indicator of significant pain in a sample of older infants. In 2000, Storm found SC 
amplitude (peaks) and number of waves (peaks/s) increased in response to heel lance, and 
returned to pre-heel lance levels in preterm infants >29 weeks gestational age (14). In a 
recent study of preterm infants 22-27 weeks GA, investigators found the combination of 
both heel lance and heel squeeze produced significant rises in SC peaks/s (26). Gladman et 
al. examined healthy term and post-term infants’ baseline and SC responses to heel lance of 
varied postmenstrual ages. In the two subgroups of infants 36-39 weeks and 40-43 weeks 
GA, investigators found a sharp rise from baseline SC to heel lance for each of the groups at 
30% and 95% respectively. While the gestational age of infants in this study was similar to 
the infants in our study, these were healthy infants without known exposure to opiates (19) .
In our study, we noted variations in the SC measures between patients. This suggests a 
within-person variability of response to stimuli; this in part may relate to individual variation 
in response to environmental challenge (12, 27). It is notable; however, that the infants that 
would require pharmacologic treatment for withdrawal within 24 hours of our observation, 
had significantly higher baseline (pre-pain phase) mean of peak SC values, and persistently 
elevated mean of peak SC levels in recovery (post-pain phase). In contrast, those infants that 
did not require later pharmacologic treatment had peak SC values which increased during 
pain phase and returned to baseline during the recovery phase. The findings of this study 
also indicate direct positive correlation between the mean of peaks SC during the pre-pain 
phase with pre-stimulation Finnegan scores.
The strengths of this study are its prospective nature and application to a population with 
well described pathophysiology and relative control of environmental and circadian 
influences known to impact SC measurement, such as time of day, infant’s behavioral state, 
handling, noise, temperature, ambient light and other noxious influences. We studied only 
opiate exposed infants with similar maternal/infant characteristics and excluded poly-drug 
exposed infants. Our approach to design and analysis included not only group differences, 
but also within group patterns of response where we identified unique phase differences 
among groups. This study used a standardized approach to obtaining both biological and 
behavioral measures of response for each study subject. Moreover, the abstinence scoring 
with MFNSS was done with pre-established inter-rater reliable nurse coders who were 
blinded to study aims and SC results.
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The major limitation of this study was our small sample size. However, we found 
statistically significant between group and within group differences in skin conductance. 
Observing serial measures of SC responses to daily care (i.e. sound and tactile stimuli) may 
have proven useful in characterizing non-painful sympathetic arousal (i.e. responses to care, 
handling) in this sample of infants. Including a comparison group of healthy term infants not 
exposed to opiates also may have proven useful. These approaches were considered but not 
undertaken in this small scale feasibility study. Time constraints related to additional 
assurances that would be required by the IRB to obtain parental authorization for screening 
infants for opiates, not part of standard care, the costs that would be incurred for the 
screening, and the sensitive nature of disclosure of the information influenced our decision 
to not study a “control” group of infants in this pilot study.
CONCLUSION
Skin conductance measures were noted to be higher at 24-48 hours of life (mean age of 
38hours) at baseline (pre-pain) and recovery (post-pain) in neonates that subsequently 
required morphine treatment by 72 hours of life for NAS, in support of our hypothesis. The 
SC measures were highly correlated with the MFNSS scores at 24-48hours of life. This 
finding has relevance as neonates with higher MFNSS scores typically require 
pharmacological therapy. Suggesting, skin conductance may be useful as an important early 
objective adjunct to MFNSS for predicting which infants will require later pharmacologic 
treatment. Skin conductance may be of particular importance not only in the early 
identification of NAS severity, but also in later therapeutic monitoring of NAS treatment. 
Further applications of these findings hold promise for the development of an early risk 
assessment to identify which neonates may require an extended period of observation and 
treatment for the symptoms of withdrawal.
In summary, we suggest that SC can be used effectively with MFNSS as an adjunct in the 
assessment of symptoms in NAS. The non-invasive nature of SC measurement, as well as its 
portability makes it an attractive tool that may permit continuous real-time monitoring of 
sympathetic arousal as seen with NAS. However, further study is required in a larger sample 
to determine the sensitivity and specificity of SC for detection of sympathetic arousal by 
NAS severity before it can be recommended for clinical application to this population and 
setting.
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List of Abbreviations
NAS Neonatal Abstinence Syndrome
MFNSS Modified Finnegan Neonatal Scoring System
SC Skin Conductance
GA Gestational Age
BW Birth Weight
HLS Heel Lance/Squeeze
WBN Well Baby Nursery
NICU Neonatal Intensive Care Unit
MFM Maternal Fetal Medicine
SE Standard Error
EMR Electronic Medical Record
IQR Inter Quartile Range
EDR Electrodermal Response (Peaks/s)
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Key Notes
• Sympathetic-mediated sweat gland filling from emotional distress or pain of 
heel-lance/squeeze was measured non-invasively via surface electrodes and 
recorded electronically.
• Skin conductance at baseline and recovery detected higher levels of sympathetic 
activation prior to the need for pharmacotherapy for neonatal abstinence 
syndrome (NAS).
• These preliminary findings will inform future investigations to evaluate the 
sensitivity and specificity of skin conductance as a test of NAS severity and 
treatment effectiveness.
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Figure 1. 
Representative subject from NAS treatment group showing continuous SC data measured 
around blood sampling done prior to the need for pharmacologic intervention for NAS. Ten 
minutes of baseline data were obtained prior to the blood sampling, next, during blood 
sampling showing noxious effects of both lance and heel squeezing, and during the 10 
minutes of recovery (post-sampling). Each waveform peak (or electrodermal response- 
EDR) is noted by a red dot. The frequency of peaks divided by the total time of the epoch in 
seconds is EDR/sec or peaks/sec. The mean height of the peaks is noted as mean of peaks.
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Figure 2. 
Correlation between skin conductance mean of peaks (μS) from the pre-heel lance phase and 
the modified Finnegan Neonatal Scoring System for infants prior to the initiation of 
pharmacologic intervention (treatment group vs non-treatment group, represents those 
requiring later treatment at 72hrs vs those not requiring treatment ). The Spearman’s (rs) 
correlation coefficient is 0.65 (P= 0.01).
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Table 1
Infant and maternal characteristics of the 14 subjects
Infant Characteristics mean ± SE, n, %
median (IQR)
Gestational age at birth, wks 38.8 ± 0.35
Birth weight, g 2850 ± 120
Gender
 Female 5, 36
Male 9, 64
5-min Apgar Score 9 (7-9)
Mode of Delivery
 Vaginal Delivery 11, 79
C-section 3, 21
Treated for NAS
Yes 6, 43
No 8, 57
Maternal Characteristics mean ± SE, n, %
Age, yrs 25 ± 1.14
Level of Education
High School 8, 57
College 6, 43
Prenatal Care
Yes 14, 100
Substance Use in Pregnancy
Methadone 10,70
Other Opiates 4, 30
Cigarette Smoking during index pregnancy 14,100
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Table 2
Between group comparisons of infants’ characteristics and skin conductance measures
Non-treated infants
mean± (SE)
n=8
Treated infants
mean± (SE)
n=6
Pvalue
Infants’ Characteristics *
GA-weeks 38.3 (0.41) 39.5 (0.51) 0.949
Age in hours at time of SC 38 (3.16) 35 (3.40) 0.347
BW-grams 2665 (98.8) 3098 (219.5) 0.025
SC Measures †
Baseline (Pre-HLS)
Mean of Peaks, μsiemens 0.04 (0.06) 0.12 (0.13) 0.020
Peaks/Sec, μsiemens 0.10 (0.08) 0.38 (0.44) 0.059
Basal Level, μsiemens 6.17 (2.71) 21.47 (13.22) 0.029
Pain Phase (HLS)
Mean of Peaks, μsiemens 0.10 (0.11) 0.32 (0.34) 0.435
Peaks/Sec, μsiemens 0.27 (0.17) 0.40 (0.19) 0.222
Basal Level, μsiemens 6.02 (2.75) 19.92 (14.09) 0.065
Recovery Phase (Post-HLS)
Mean of Peaks, μsiemens 0.04 (0.06) 0.26 (0.17) 0.048
Peaks/Sec, μsiemens 0.09 (0.10) 0.21 (0.20) 0.268
Basal Level, μsiemens 6.15 (2.89) 16.43 (13.66) 0.073
HLS = Heel lance/squeeze,
*
Difference by Independent samples t test,
†
Difference by Mann Whitney U test
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